Predictors of dyskinesia: STRIDE-PD analysis


REPORT FROM THE 15TH INTERNATIONAL MEETING OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS, TORONTO, JUNE 5-9, 2011 – A number of clinical studies have demonstrated the benefits of entacapone, a catechol-O-methyltransferase (COMT) inhibitor, in combination with levodopa-carbidopa in PD patients with motor fluctuations (Parkinson Study Group. Ann Neurol 1997; 42: 747-755; Rinne et al. Neurology 1998; 51: 186-189).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page